Carisma Therapeutics, Inc.CARMNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+46.8%
5Y CAGR+18.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+46.8%/yr
Quarterly compound
5Y CAGR
+18.0%/yr
Recent acceleration
Percentile
P95
Near historical high
vs 5Y Ago
2.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 132.32% |
| Q2 2025 | 41.35% |
| Q1 2025 | -20.53% |
| Q4 2024 | 35.85% |
| Q3 2024 | 19.23% |
| Q2 2024 | 28.12% |
| Q1 2024 | -39.31% |
| Q4 2023 | 23.34% |
| Q3 2023 | -13.22% |
| Q2 2023 | 27.36% |
| Q1 2023 | -30.61% |
| Q4 2022 | -134.95% |
| Q3 2022 | 41.81% |
| Q2 2022 | -141.32% |
| Q1 2022 | 374.63% |
| Q4 2021 | 14.06% |
| Q3 2021 | 36.64% |
| Q2 2021 | -25.26% |
| Q1 2021 | -117.12% |
| Q4 2020 | -112.62% |
| Q3 2020 | 57.82% |
| Q2 2020 | -7.35% |
| Q1 2020 | 35.98% |
| Q4 2019 | -97.98% |
| Q3 2019 | 20.32% |
| Q2 2019 | -9.50% |
| Q1 2019 | -4.51% |
| Q4 2018 | -46.97% |
| Q3 2018 | 7.02% |
| Q2 2018 | -27.68% |
| Q1 2018 | -20.91% |
| Q4 2017 | 18.26% |
| Q3 2017 | 1.66% |
| Q2 2017 | 13.19% |
| Q1 2017 | 5.82% |
| Q4 2016 | -125.42% |
| Q3 2016 | 533.16% |
| Q2 2016 | 41.42% |
| Q1 2016 | 8.86% |
| Q4 2015 | -22.77% |